Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis
article
OA: closed
CC0
⤵ 37 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This study evaluated the effectiveness of intranasal and subcutaneous luteinizing hormone-releasing hormone agonist administration in suppressing ovarian function for endometriosis treatment.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (9)
- Endometriosis: Role of Ovarian Steroids in Initiation, Maintenance, and Suppression via openalex
- Gonadotropin-Releasing Hormone Agonist Suppresses Ovulation, Menses, and Endometriosis in Monkeys: An Individualized, Intermittent Regimen* via openalex
- Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist via openalex
- Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. via openalex
- Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin) via openalex
- W2408619637 via openalex
- W2418323373 via openalex
- W2477008945 via openalex
- W6607058909 via openalex
Cited by (37)
- Weighing up GnRH agonist therapy for endometriosis: outcomes and the treatment paradigm 2025
- A review of phase II and III drugs for the treatment and management of endometriosis 2023
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- Advances in targeting estrogen synthesis and receptors in patients with endometriosis 2022
- Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis 2020
- A comprehensive review of hormonal and biological therapies for endometriosis: latest developments 2019
- Current and emerging treatment options for endometriosis 2018
- Traitement médical de l’endométriose : prise en charge de la douleur et de l’évolution des lésions par traitement hormonal. RPC Endométriose CNGOF-HAS 2018
- Current and Emerging Therapeutics for the Management of Endometriosis 2018
- Traitement médical de l’endométriose : prise en charge de la douleur et de l’évolution des lésions par traitement hormonal et perspectives thérapeutiques 2017
- Treatment of pain associated with deep endometriosis: alternatives and evidence 2015
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 2010
- Endometriose 2009
- Pain scoring in endometriosis: entry criteria and outcome measures for clinical trials. Report from the Art and Science of Endometriosis meeting 2008
- Endometriose 2005
- Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study 2002
- Medical and Surgical Therapies for Pain Associated with Endometriosis 2001
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 1999
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 1999
- The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover 1998
- The evidence for the management of endometriosis 1998
- Management of Stage III and IV endometriosis: a 10-year experience 1994
- 9 Endometriosis: Medical therapy 1993
- Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study 1993
- Endocrine Treatment of Endometriosis 1992
- Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol 1991
- Time-related effects of gonadotropin-releasing hormone analog treatment in experimentally induced endometriosis in the rat 1991
- Menses due to endometriosis in a woman following hysterectomy 1990
- Gonadotrophin releasing hormone agonist (buserelin) in the treatment of endometriosis: changes in the extent of the disease and in CA 125 serum levels after 6‐month therapy 1990
- Endometriosis and infertility 1990
- Elevated peritoneal fluid luteinizing hormone and prolactin concentrations in infertile women with endometriosis 1990
- Calcium Metabolism in Premenopausal Women Treated by a Gn-RH Agonist for Uterine Myoma. 1990
- Comparison of Buserelin to Danazol Therapy in Endometriosis 1990
- Comparison of Buserelin to Danazol Therapy in Endometriosis 1990
- Endometriosis-associated infertility treated by long-term gonadotropin-releasing hormone agonist administration and assisted fertilization 1990
- Buserelin 1990
- Metabolic changes during medical treatment of endometriosis: Nafarelin acetate versus danazol 1989
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:09:25.758913+00:00
License: CC0
· commercial use OK